Seroprevalence, cost per donation and reduction in blood supply due to positive and indeterminate results for infectious markers in a blood bank in Lima, Peru

Abstract

IntroductionSafety in Transfusion Medicine is subject to regulations and government legislation within a total quality framework. The aim of this study was to evaluate the impact of seroprevalence and indeterminate results on lost units and cost per donation.MethodsA prospective cross-sectional study was performed in the Blood Bank and Transfusion Therapy Department of the Hospital Central de la Policia Nacional del Perú in Lima, Peru. All completed donations (replacement/voluntary) without complications were included in this study. Every donation met the institutional requirements and quality criteria of Programa Nacional de Hemoterapia y Bancos de Sangre (PRONAHEBAS). Data analysis was achieved using the Statistical Package for the Social Sciences.ResultsA total of 7723 donations were evaluated during 2014 and 2015 with 493 being seropositive (overall prevalence 5.25%) and 502 having indeterminate results (overall prevalence 5.35%). Thus total loss was 995 units, 437.8 L of blood and 49,750 US dollars. The most common seropositive infectious markers were the core antibody of hepatitis B virus (2.82%) and syphilis (1.02%), and the most common indeterminate results were Chagas disease (1.27%) and the core antibody of hepatitis B virus (1.26%). There was no significant change in the prevalence of seropositivity (p-value = 0.243) or indeterminate results (p-value = 0.227) over the two-year period of the study. A statistical correlation was found between the cost per lost donation and the most prevalent markers (rho = 0.848; p-value = <0.001).ConclusionSeroprevalence was lower than the regional mean, but the prevalence of indeterminate results was elevated causing a great impact on blood supply and economic losses to this institution.

Economic evaluations addressing diagnosis and treatment strategies for neglected tropical diseases: an overview

“…In the case of Chagas disease, the set of evidence consolidated by several studies advocates in favor of serological testing of donors in blood bank as well as in antenatal screening [20][21][22][23][24][25][26][27][28] as cost-effective public health strategies. These results corroborate the resolution of the World Health Assembly, which recommends Chagas disease screening for pregnant women in non-endemic areas if they were born in disease-endemic areas, if they have lived for a long time in disease-endemic areas, or if they were born to mothers who lived in disease-endemic areas 57 .…”

“…In Peru, Moya-Salazar et al 25 evaluated the impact of seroprevalence and indeterminate results on lost units and cost per donation. A total of 7,723 donations were evaluated and the total loss was of 49,750 US dollars.…”

Evaluation of the Chagas Western Blot IgG Assay for the Diagnosis of Chagas Disease

“…In France, a non-endemic area, a study in 2011 by the French Blood bank [13] showed that, among the 163,740 donations that had been tested for Chagas disease (3.5% of the total donations), five were positive and close to 1400 indeterminate (0.85%). In Peru, a recent study [14] showed that, of 7723 donations evaluated for Chagas disease in 2014 to 2015, ten were positive (overall prevalence 0.14%) and 98 indeterminate (overall prevalence 1.27%). In both of these examples, the number of indeterminate results was superior to that of the positive results.…”

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru

“…As part of the quality requirements of public and private Hemotherapy and Blood Bank centres, there is the imperative to know the needs and health realities of its users and to effectively meet all the requirements of cancer patients. Therefore, the Blood Banks must possess stocks of the most demanded blood products and a constant flow of high-quality pathogen-free donations [ 27 ].…”